Abstract：
BACKGROUND: Crohn\'s disease and ulcerative colitis are inflammatory bowel diseases (IBDs) with a rapidly growing worldwide incidence. The last decades presented rapid progress in pharmacological treatment leading in many cases to clinical and endoscopic remission, including biological treatment with anti-TNF agents.
OBJECTIVE: The exact timing of introduction, optimization and maintenance of anti-TNF therapy in IBDs is not thoroughly covered in current guidelines.
METHODS: We used the Delphi panel methodology to gather the IBD experts\' views and achieve consensus for clinical recommendations on introducing and maintaining anti-TNF therapy for patients with IBDs.
RESULTS: Twelve recommendations achieved a high level of consensus in two assessment rounds by 52 (1st round) and 47 (2nd round) IBD experts.
CONCLUSIONS: In many clinical situations, the early use of anti-TNF therapy is recommended. Nowadays, the cost-efficacy profile of anti-TNF biosimilars makes them the first-line drug in a substantial proportion of patients, thus providing the opportunity to increase access to biological therapy.
OBJECTIVE: The exact timing of introduction, optimization and maintenance of anti-TNF therapy in IBDs is not thoroughly covered in current guidelines.
METHODS: We used the Delphi panel methodology to gather the IBD experts\' views and achieve consensus for clinical recommendations on introducing and maintaining anti-TNF therapy for patients with IBDs.
RESULTS: Twelve recommendations achieved a high level of consensus in two assessment rounds by 52 (1st round) and 47 (2nd round) IBD experts.
CONCLUSIONS: In many clinical situations, the early use of anti-TNF therapy is recommended. Nowadays, the cost-efficacy profile of anti-TNF biosimilars makes them the first-line drug in a substantial proportion of patients, thus providing the opportunity to increase access to biological therapy.
摘要：
背景：克罗恩病和溃疡性结肠炎是炎症性肠病（IBDs），在全球范围内发病率迅速增长。在过去的几十年中，药物治疗取得了快速进展，在许多情况下导致临床和内窥镜缓解。包括抗TNF药物的生物治疗。
目的：引入的确切时间，目前的指南并未完全涵盖IBD中抗TNF治疗的优化和维持.
方法：我们使用Delphi小组方法收集IBD专家的观点，并就IBD患者引入和维持抗TNF治疗的临床建议达成共识。
结果：12项建议在两轮评估中获得了52名（第一轮）和47名（第二轮）IBD专家的高度共识。
结论：在许多临床情况下，建议早期使用抗TNF治疗.如今,抗TNF生物仿制药的成本-疗效特征使其成为相当大比例患者的一线药物，从而提供了增加获得生物治疗的机会。
目的：引入的确切时间，目前的指南并未完全涵盖IBD中抗TNF治疗的优化和维持.
方法：我们使用Delphi小组方法收集IBD专家的观点，并就IBD患者引入和维持抗TNF治疗的临床建议达成共识。
结果：12项建议在两轮评估中获得了52名（第一轮）和47名（第二轮）IBD专家的高度共识。
结论：在许多临床情况下，建议早期使用抗TNF治疗.如今,抗TNF生物仿制药的成本-疗效特征使其成为相当大比例患者的一线药物，从而提供了增加获得生物治疗的机会。
